Physician profile
Mark A Griffith
NPI 1619007440
$2,298.66
in general payments reported to CMS, 2019-2025
18 companies · $77.70 in 2025
The $77.70 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,276 · 2022: $552 · 2023: $107 · 2024: $285 · 2025: $77.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $351.09 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $282.47 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $241.84 | 2021-2022 | |
| Abbott Laboratories | $210.00 | 2021-2025 | Aveir, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.35 | 2021-2022 | |
| Pfizer INC. | $172.82 | 2021-2025 | |
| Esperion Therapeutics, INC. | $158.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $130.45 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $127.35 | 2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $105.53 | 2021-2024 | Eliquis |
| Abbvie INC. | $74.72 | 2023-2024 | |
| Amgen INC. | $72.31 | 2021-2022 | |
| Amarin Pharma, INC. | $51.50 | 2021-2022 | |
| Boston Scientific Corporation | $44.85 | 2022-2025 | Watchman Access System |
| Melinta Therapeutics, LLC | $37.36 | 2024 | Rezzayo, Kimyrsa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $29.41 | 2024 | Arcalyst |
| Chiesi USA, INC. | $18.91 | 2021 | |
| Terumo Medical Corporation | $15.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.